March 11 (Reuters) - The U.S. FDA has declined to approve Viatris and Mapi Pharma's once-a-month injection for the treatment of relapsing forms of multiple sclerosis, the companies said on Monday. (Reporting by Sriparna Roy and Sneha S K in Bengaluru; Editing by Pooja Desai)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
11.88 USD | +1.32% | +2.11% | +9.65% |
18/04 | Viatris' Proposed Femoston, Duphaston UK Rights Divestment Being Considered, CMA Says | MT |
18/04 | UK Regulator to Consider Undertakings for Theramex-Viatris Deal | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
2,706 PTS | -1.45% | -1.34% | - | ||
11.88 USD | +1.32% | +2.11% | 13.92B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.65% | 13.92B | |
+33.39% | 700B | |
-4.89% | 358B | |
+18.85% | 330B | |
+3.42% | 287B | |
+15.70% | 236B | |
+6.68% | 202B | |
-9.08% | 197B | |
+5.51% | 161B | |
-2.19% | 157B |
- Stock Market
- Equities
- VTRS Stock
- News Viatris Inc.
- US FDA declines to approve Viatris's injection for multiple sclerosis